Marcelo Kremenchutzky, MD, FRCPC, FAAN
Associate Professor of Neurology, Western University
Office: London Health Sciences Centre, University Hospital A10 - 308
Dr. Kremenchutzky had the privilege and the honour of being mentored by, and subsequently working with, world leaders in neurology in London and elsewhere such as Dr. George C. Ebers and Dr. George P. A. Rice. As a Western researcher, his contributions to epidemiology and natural history of Multiple Sclerosis work are listed amongst the seminal contributions to the modern understanding of MS. He designed and implemented the first ever study of this kind in South America [the Patagonia MS Project] that led the way to well organized efforts by the group of researchers to further develop and accumulate research data for MS in the austral subcontinent - a place where MS used to be considered a rare disease and it is now known to be more common than expected. Patients are better managed now thanks at least in part to his efforts as a Founding Member of the above mentioned group as well as LACTRiMS [Latin American Committee for the Treatment and Research in Multiple Sclerosis]. He has always made an effort to apply findings from basic science to enhance human health and well-being. In the MS research context, he aims to "translate" findings in fundamental research into medical practice and meaningful health outcomes for people living with MS and their families. He has published nearly 100 full text papers and over 200 abstracts. As a Lawson Scientist he has been Principal and Site Investigator in over 200 clinical trials, research projects and other multi-year multi-million grants, including ongoing CIHR funded research in ultra-high field MRI research in MS through cooperation with Western’s Centre for Functional and Metabolic Mapping at the Robarts Research Institute.
The London MS Clinic had a formidable track record spanning over 40 years, the last 20 with Dr. Kremenchutzky’s participation and over a decade under his Directorship. During his tenure as Director he established a second to none interdisciplinary basic clinical research program, with groundbreaking projects in terms of new treatment development as well as novel original basic-clinical research network creation and development, including all the pivotal trials that lead to the approval of currently available treatments in MS in Canada and the World.
As a clinical neurologist Dr. Kremenchutzky dedicated the last 20 years [almost half of this time as the only MS specialist at LHSC] of service to MS patients and their families in his clinic with nearly 6,000 patients on record, coming from all corners of our large Province, including areas normally serviced by other Clinics. His evolving role in the clinic made him the first ever Chapman Chair in MS Clinical Research in London [Ont] yet patients still find in him someone who knows them by first name, understands their needs, and would always make time for a more holistic and personable patient-doctor approach at a time when their whole world seems to turn more impersonal and interactions with healthcare professionals more ‘mechanical’.
He is the Vice/Co-Chair or Acting Chair of the Western Health Sciences Research Ethics Board [which involves policy development and implementation of change], and other academic activities. In 2016 he was honoured to be the key note speaker at Western’s Science Student’s Council’s Discovery Week and was nominated to the Royal Society of Canada. He have given dozens of research lectures, talks, and interviews to local and international medical and non-medical professionals and lay organizations. He has received Research Awards and recognition from government agencies [ACE award from the Ontario Ministry of Health], Universities [Teaching Honour Roll from Western’s Students Council], etc that have honoured his contributions to the MS field.
Dr. Kremenchutzky's main interest is the study of MS and other demyelinating disorders, focusing on the epidemiology, natural history and treatment of this still mysterious disease. His most recent research has focused on the much under investigated nature of progressive MS. In addition to his own research, Dr. Kremenchutzky is currently involved in clinical trials to study new treatments in MS. It is his hope that these endeavors will contribute to a breakthrough in the much desired yet still evasive cure for people living with MS.
Honours and Awards
- 2012 - Best Advance in Multiple Sclerosis, American Academy of Neurology
- 2002 - Teaching Honour Roll Certificate for Excellence in Teaching Medicine, University Students' Council, Western University
Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889. PMID: 28564557
Budhram A, Pelikan JB, Kremenchutzky M, Sharma M. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol Sci. 2017 Apr 15;375:304-306. doi: 10.1016/j.jns.2017.02.021. Epub 2017 Feb 10. No abstract available. PMID: 28320156
Budhram A, Parvathy S, Kremenchutzky M, Silverman M. Breaking down the gut microbiome composition in multiple sclerosis. Mult Scler. 2017 Apr;23(5):628-636. doi: 10.1177/1352458516682105. Epub 2016 Dec 12. PMID:27956557
- Common acne medication offers new treatment for multiple sclerosis - Science Daily
- Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA™ (Daclizumab Beta) for Multiple Sclerosis - Cision
- Better MS Tracking Tool Developed by Robarts Institute Scientists At University of Western Ontario - Multiple Sclerosis News Today
- New MS drug showing promise for patients - CTV
- Health Canada Approves TECFIDERA™ As A First-Line Oral Treatment For Multiple Sclerosis - Cision
- UCSF Study Revisits First Clinical Trial to Treat Multiple Sclerosis Decades Later - University of California San Francisco
Social Media Coverage
Dr. Kremenchutzky & #WesternU Researchers launch first FMT Study in humans today to further investigate #gutbacteria as potential therapy for #MultipleSclerosis #WorldFirst @MSSocietyCanada #MS #research #endMS— #WesternU CNS (@westernuCNS) November 9, 2017